Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2004-05-19
2008-12-16
Campell, Bruce (Department: 1648)
Chemistry: molecular biology and microbiology
Vector, per se
C435S237000, C435S326000, C424S152100, C424S230100
Reexamination Certificate
active
07465580
ABSTRACT:
The invention provides a vector encoding a derivative of EBNA-1 that is not cytotoxic when expressed efficiently in cells, which supports extrachromosomal replication, maintenance and transcription from extrachromosomal oriP containing vectors but does not substantially activate transcription from host cell genes. Also provided is a vector having oriP and encoding a derivative of EBNA-1. The vectors of the invention may be employed in vitro and in gene therapy.
REFERENCES:
patent: 4686186 (1987-08-01), Sugden
patent: 5194601 (1993-03-01), Sugden
patent: 5707830 (1998-01-01), Calos
patent: 2002/0068354 (2002-06-01), Johnson et al.
patent: 2003/0099936 (2003-05-01), Sugden et al.
patent: 2003/0109475 (2003-06-01), Debs et al.
patent: WO 00/47778 (2000-08-01), None
Hung et al., Maintenance of EBV oriP-based spisomes requires EBV-encoded nuclear antiten-1 chromosome-binding domains, which can be replaced by high-mobility group-I or histone H1, Proceedings of the National Academy of Sciences of the United States of America (PNAS), Feb. 2001, vol. 98, No. 4, pp. 1865-1870.
Aiyar, A., et al., “The Plasmid Replicon of EBV Consists of Multiple cis-Acting Elements that Facilitate DNA Synthesis by the Cell and a Viral Maintenance Element”,The EMBO Journal, 17(21), (1998),6394-6403.
Arrand, J R., et al., “Molecular cloning of the Complete Epstein-Barr Virus Genome as a Set of Overlapping Restriction Endonuclease Fragments”,Nucleic Acids Research, 9(13), (Jul. 10, 1981),2999-3014.
Baer, R J., et al., “DNA Sequence and Expression of the B95-8 Epstein-Barr Virus Genome”,Nature, 310(5974), (1984),207-211.
Bankier, A T., et al., “DNA Sequence Analysis of theEcoRI Dhet Fragment of B95-8 Epstein-Barr Virus Containing the Terminal Repeat Sequences”,Molecular Biology and Medicine, 1(4), (1983),425-445.
Bankier, A T., et al., “Sequence Analysis of the 17,166 Base-PairEcoRI Fragment C of B95-8 Epstein-Barr Virus”,Molecular Biology and Medicine, 1(1), (Jul. 1983),21-45.
Biggin, M , et al., “Transcription and DNA Sequence of theBamHI L Fragment of B95-8 Epstein-Barr Virus”,The EMBO Journal, 3(5), (May 1984), 1083-1090.
Deininger, P L., et al., “Sequence Analysis and in Vitro Transcription of Portions of the Epstein-Barr Virus Genome”,Journal of Cellular Biochemistry, 19(3), (1982),267-74.
Farrell, P J., et al., “Homologous Upstream Sequences Near Epstein-Barr Virus Promoters”,Proc. Natl. Acad. Sci. USA., 80(6), (1983),1565-1569.
Farrell, P J., et al., “Latent and Lytic Cycle Promoters of Epstein-Barr Virus”,The EMBO Journal, 2(8), (1983), 1331-1338.
Gibson, T., et al., “Homology Between Two EBV Early Genes and HSV Ribonucleotide Reductase and 38K Genes”,Nucleic Acids Research, 12(12), (1984),5087-5099.
Holowaty, M. N., et al., “Protein Profiling With Epstein-Barr Nuclear Antigen-1 Reveals an Interaction With the Herpesvirus-Associated Ubiquitin-Specific Protease HAUSP/USP7”,The Journal of Biological Chemistry, 278(32), (2003),29987-29994.
Huang, N E., et al., “Modulation of YY1 Activity by SAP30”,Biochemical and Biophysical Research Communications., vol. 306(1), (2003),267-275.
Humme, S., et al., “The EBV Nuclear Antigen 1 (EBNA1) Enhances B Cell Immortalization Several Thousandfold”,Proc. Natl. Acad. Sci. USA, 100(19), (2003), 10989-10994.
Jeang, K T., et al., “Organization of the Epstein-Barr Virus DNA Molecule. III. Location of the P3HR-1 Deletion Junction and Characterization of theNotl Repeat Units that Form Part of the Template for an Abundant 12-O-Tetradecanoylphorbol-13-Acetate-Induced mRNA Transcript”,Journal of Virology, 48(1), (1983),135-148.
Jones, R. J., et al., “Epstein-Barr Virus Nuclear Antigen 1 (EBNA1) Induced Cytotoxicity in Epithelial Cells is Associated With EBNA1 Degradation and Processing”,Virology, 313, (2003),663-676.
Jones, M D., et al., “The EB Virus Genome in Daudi Burkitt's Lymphoma Cells has a Deletion Similar to that Observed in a Non-Transforming Strain (P3HR-1) of the Virus”,The EMBO Journal, 3(4), (1984),813-821.
Kaneda, Y., “Improvements in Gene Therapy Technologies”,Molecular Urology, 5(2), (2001),85-89.
Kang, M.-S., et al., “Epstein-Barr Virus Nuclear Antigen 1 Activates Transcription From Episomal But Not Integrated DNA and Does Not Alter Lymphocyte Growth”,Proc. Natl. Acad. of Sci. USA, 98(26), (2001),15233-15238.
Kennedy, G., et al., “Chapter 3.2 Virus-Based Vectors for Gene Expression in Mammalian Cells: Epstein-Barr Virus”,In: Gene Transfer and Expression in Mammalian Cells, S. C. Makrides, Editor, Elsevier Science B.V., Publisher,(2003),55-70.
Kennedy, G , et al., “EBNA-1, a Bifunctional Transcriptional Activator”,Molecular Cellular Biology, 23(19), (2003),6901-6908.
Kennedy, G., et al., “Epstein-Barr Virus Provides a Survival Factor to Burkitt's Lymphomas”,Proc. Natl. Acad. Sci. USA., 100(24), (2003), 14269-14274.
Kozak, M., “Possible Role of Flanking Nucleotides in Recognition of the AUG Initiator Codon by Eukaryotic Ribosomes”,Nucleic Acids Research, 9(20), (1981),5233-52.
Kurisaki, K., et al., “Nuclear Factor YY1 Inhibits Transforming Growth Factor beta- and Bone Morphogenetic Protein-Induced Cell Differentiation”,Molecular and Cellular Biology., vol. 23(13), (2003),4494-4510.
Laux, G., et al., “A Spliced Epstein-Barr Virus Gene Expressed in Immortalized Lymphocytes is Created by Circularization of the Linear Viral Genome”,The EMBO Journal, 7(3), (1988),769-774.
Leight, E. R., et al., “EBNA-1: A Protein Pivotal to Laten Infection by Epstein-Barr Virus”,Reviews in Medical Virology, 10, (2000),83-100.
Levitskaya, J. , et al., “Inhibition of Antigen Processing by the Internal Repeat Region of the Epstein-Barr Virus Nuclear Antigen-1”,Nature, 375, (1995),685-688.
Mazda, O., “Improvement of Nonviral Gene Therapy by Epstein-Barr Virus (EBV)-based Plasmid Vectors”,Current Gene Therapy, 2(3), (2002),379-392.
Parker, B D., et al., “Sequence and Transcription of Raji Epstein-Barr Virus DNA Spanning the B95-8 Deletion Region”,Virology, 179(1), (1990),339-346.
Séguin, C , et al., “DNA Sequence and Transcription of theBamHI Fragment B Region of B95-8 Epstein-Barr virus”,Mol Biol Med., 1(3), (1983),369-392.
Shire, K. , et al., “EBP2, a Human Protein That Interacts With Sequences of the Epstein-Barr Virus Nuclear Antigen 1 Important for Plasmid Maintenance”,Journal of Virology, 73(4), (1999),2587-2595.
Sucharov, C C., et al., “Yin Yang 1 is Increased in Human Heart Failure and Represses the Activity of the Human α-Myosin Heavy Chain Promoter”,The Journal of Biological Chemistry, vol. 278(33), (2003),31233-31239.
Sugden, B., et al., “EBV's Plasmid Replicon: an Enigma incisandtrans”,Current Topics in Microbiology and Immunology, 258, (2001),3-11.
Sugden, B., “In the Beginning: A Viral Origin Exploits the Cell”,Trends in Biochemical Sciences, 27(1), (2002),1-3.
Wu, H., et al., “Separation of the DNA Replication, Segregation, and Transcriptional Activation Functions of Epstein-Barr Nuclear Antigen 1”,Journal of Virology, 76(5), (2002),2480-2490.
Yates, J., et al., “Acis-Acting Element from the Epstein-Barr Viral Genome that Permits Stable Replication of Recombinant Plasmids in Latently Infected Cells”,Proc. Natl. Acad. Sci. USA., 81(12), (Jun. 1984),3806-3810.
Yin, Y., et al., “Self-Inhibition of Synthesis and Antigen Presentation by Epstein-Barr Virus-Encoded EBNA1”,Science, 301, (2003),1371-1374.
Bodescot, M., et al., “Clustered Alternative Splice Sites in Epstein-Barr Virus RNAs”,Nucleic Acids Research, 15(14), (1987),5887.
Kennedy Gregory Dean
Sugden William M.
Wang Jindong
Campell Bruce
Hurt Sharon
Schwegman Lundberg & Woessner, P.A.
Wisconsin Alumni Research Foundation
LandOfFree
Non-cytotoxic oriP replicon does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-cytotoxic oriP replicon, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-cytotoxic oriP replicon will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4046632